Healius Eyes Agilex Biolabs Sale and Lifts FY2026 Earnings Guidance
Healius flags Agilex Biolabs sale and lifts FY2026 earnings guidance
Healius Limited (ASX: HLS) has issued a FY2026 trading update alongside a significant strategic announcement: the company is exploring a Healius Agilex Biolabs strategic sale, having engaged UBS Securities Australia Limited to assist in the process. The decision follows “unsolicited approaches from credible parties,” with the company framing the review as part of its “ongoing program to optimise shareholder value.” On the earnings front, Healius now expects Group Underlying EBITDA of $259.0m–$264.0m and Group Underlying EBIT of $30.0m–$35.0m for FY2026. Critically, any sale of Agilex Biolabs would not impact Healius’ core Pathology operations, given Agilex’s status as a standalone business within the Group.
When big ASX news breaks, our subscribers know first
What investors need to know about the Agilex Biolabs sale process
Why Healius is exploring a sale now
The formal sale process stems from what Healius described as an “ongoing program to optimise shareholder value,” accelerated by multiple “unsolicited approaches from credible parties” that the company deemed material enough to pursue. To manage the process, UBS Securities Australia Limited has been formally engaged as financial adviser. The company has been clear that Agilex Biolabs operates independently within the Group structure, meaning a transaction would leave Healius’ Pathology platform intact and unaffected.
Investors can expect a formal update no later than August 2026, when Healius is scheduled to deliver its full year financial results presentation, though the company noted it would communicate earlier if circumstances required.
Agilex Biolabs by the numbers
The commercial momentum behind Agilex Biolabs is central to the buyer interest the company has attracted. Key metrics from the FY2026 year to date include:
- Revenue grew 13.7% for the year to date
- The business “continues to trade strongly,” per the company’s announcement
- Agilex operates as a standalone unit, making it a clean, separable asset
No sale price, valuation, or indicative offer has been disclosed by Healius at this stage.
What is Agilex Biolabs?
Agilex Biolabs is a specialty clinical research and bioanalytical services business operating within the Healius Group. It provides laboratory testing and scientific services primarily to pharmaceutical and biotechnology clients developing new medicines, rather than to patients directly.
A standalone division with its own revenue base, client contracts, and operational infrastructure is generally more attractive to strategic buyers than an embedded business unit would be. The combination of fast revenue growth (13.7% year to date), a separable structure, and an established client base in a high-demand sector helps explain why credible parties have approached Healius without prompting.
FY2026 trading update: pathology performance and cost pressures
Revenue growth versus volume softness
Healius’ Pathology segment has shown a notable divergence between volumes and revenue across FY2026. While volumes declined 0.4% for the 10 months to April 2026, revenue still grew 2.4% over the same period, pointing to favourable pricing and test-mix dynamics offsetting softer demand. General practitioner (GP) attendance, a leading indicator for pathology referrals, declined 1.5% in the first half of FY2026 and a further 1.0% for the January to March 2026 period. These are sector-wide headwinds rather than company-specific issues.
| Period | Volume Growth | Revenue Growth | Cost Growth |
|---|---|---|---|
| 1H 2026 | +1.2% | +3.5% | — |
| 10 months to April 2026 | -0.4% | +2.4% | +1.1% |
Cost containment and Fair Work Commission impacts
Pathology costs grew just 1.1% for the 10 months to April 2026, a deliberate step down from the 1.9% reported at December 2025. Labour cost reductions are flowing through in the second half of FY2026 as anticipated, with further efficiencies flagged by management.
However, a new cost pressure has emerged through the Fair Work Commission’s findings on “gender-based undervaluation.” The timeline for these impacts is as follows:
- A $1.8m cost hit in Q4 FY2026, applying from 1 April 2026, relates to the initial increase for Pathology Collectors
- A further Pathology Collector increase is scheduled for 1 January 2027
- Health Professionals will receive a phased increase in equal instalments over five years, commencing 1 July 2026
A final determination on rates and classifications has not yet been delivered by the Fair Work Commission, leaving some uncertainty around the full quantum of future increases. Inclusive of these Fair Work Commission adjustments, Pathology labour costs have increased 0.8% for the 10 months to April 2026, against prior guidance of broadly flat for FY2026.
Federal Budget: no new pathology funding
The Federal Budget delivered on 12 May 2026 contains no new funding for pathology, a sector that Healius notes is already operating under an indexation freeze for most tests. The 2024–25 Budget had partially restored indexation, but changes to Medicare criteria for B12 and urine testing effective 1 July 2025 more than offset those gains.
Healius has stated that inadequate funding has already resulted in staff cuts, collection centre closures, and regional laboratory rationalisations. The company further indicated that charging out-of-pocket fees for pathology tests may become necessary to bridge the funding gap, a significant statement for a sector that has historically operated under a bulk-billing model. Investors should treat this as a medium-term cost and revenue risk for the Pathology segment, particularly given the concurrent Fair Work Commission wage pressures.
The next major ASX story will hit our subscribers first
What’s next for Healius investors
Two catalysts are worth monitoring in the near term. First, the Agilex Biolabs sale process, with the next formal update expected at the August 2026 full year results presentation. A completed transaction could unlock capital and allow Healius to concentrate resources on its core Pathology platform. Second, the ongoing cost efficiency programme within Pathology, with management signalling further labour savings expected to materialise across the remainder of FY2026.
Against this backdrop, Healius has guided to Group Underlying EBITDA of $259.0m–$264.0m and Group Underlying EBIT of $30.0m–$35.0m for FY2026. The potential Agilex sale, if completed, would represent a meaningful capital event that reshapes the Group’s asset profile and investment thesis.
Don’t Miss the Next Healthcare Breakout on the ASX
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts today.